2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Basal Cell
11
Medulloblastoma
6
Skin Neoplasms
4
Recurrence
4
Basal Cell Nevus Syndrome
4
Thrombocythemia, Essential
2
Prostatic Neoplasms
2
Primary Myelofibrosis
2
Polycythemia Vera
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Basal Cell
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Glioma
2
Glioblastoma
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Breast Neoplasms
2
Astrocytoma
2
Thrombocytosis
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pyloric Stenosis, Hypertrophic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Interventions
Cyclophosphamide
87
fludarabine
77
fludarabine phosphate
45
Tacrolimus
45
Whole-Body Irradiation
42
Mycophenolic Acid
42
Busulfan
35
Melphalan
32
Antilymphocyte Serum
24
Methotrexate
23
thymoglobulin
22
Standard of Care
22
Rituximab
22
venetoclax
20
Thiotepa
20
Sirolimus
20
Azacitidine
20
Stem Cell Transplantation
18
Granulocyte Colony-Stimulating Factor
18
Practice Guidelines as Topic
17
Cytarabine
16
Bortezomib
16
Nivolumab
15
Filgrastim
15
Specimen Handling
14
Dexamethasone
14
Blood Specimen Collection
14
Cyclosporine
13
Surveys and Questionnaires
12
Mesna
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
sonidegib
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts